Dr. Vincent Dammai MS, MBA, MPH, PhD
President/CEO : Solid tumor Advanced Therapeutics - Cell & Gene Therapy, ATMP Biologics manufacturing
Expert in Molecular Biology, Cell Biology, Developmental Biology, Biologics Drug Discovery and Cell Therapy. Dr. Dammai’s post-doctoral training at the Salk Institute for Biological Studies, La Jolla, California and University of California San Diego (UCSD) was followed by university faculty position as a NIH/National Cancer Institute (NCI)-funded (RO1 grant) Principal Investigator (Group Leader) and College of Medicine Assistant Professor at the NCI-designated Hollings Cancer Center, Charleston for 11 years prior to stepping outside academics to lead translational research in private biotech industry and subsequently partnership in entrepreneurial ventures. Dr.Dammai's PhD work focused on successful design and pre-clinical testing of catalytic RNAs (ribozymes) as RNA therapeutics approach to reverse Rheumatoid Arthritis (RA) disease progression. Dr.Dammai's subsequent research studies firmly stand as landmark discoveries of fundamental mechanisms in biology. Dr.Dammai served as an External Director of Research for private biotech companies involved in biologics discovery and pre-clinical/clinical development. While in academia, Dr.Dammai's research programs were funded by National Institutes of Health (NIH/NCI) and US Department of Defense (DOD) and his university leadership included faculty senator, Institutional Advancement Committee member, advisory committee member for Cancer Proteomics, advisory committee member for Biological Imaging Core Facility, and Director and c0-Director of PhD and MD/PhD programs in Molecular and Cell Biology. He served as an area expert in translational medicine for a number of years for American Cancer Society (ACS), DOD, National Aeronautics and Space Administration (NASA) and the Italian Ministry of Health, Italy. Dr.Dammai has the breadth of knowledge in diverse fields of biomedical sciences and bioengineering, especially in Cell & Gene Therapy (ATMP) areas with respect to R&D, CMC and MS&T. He is an expert in RNA-, Gene - and Cell therapeutics R&D, manufacturing and pre/clinical development. Dr.Dammai led the development of novel tumor seeking vehicles to target kidney cancers by modifying Sindbis Virus genome for tumor-specific delivery of ‘smart’ therapeutic payloads and oncolytic self-amplifying RNA (samRNA). Dr.Dammai’s research identified tumor-specific “neoantigens” and unique surface/secreted proteins for kidney cancers that formed the basis for designing these novel strategies to activate immune recognition of solid tumors. Dr.Dammai is published in top-tier journals such as CELL, Nature Cell Biology, Genes & Development, Molecular & Cellular Biology, Cancer Research, Journal of Biological Chemistry, Gene Therapy etc. Dr.Dammai also served as President/CEO of Biosimilars & Biologics Inc., a venture promoted by DMSC, which recently exited. Pubmed Publications
Expert in Molecular Biology, Cell Biology, Developmental Biology, Biologics Drug Discovery and Cell Therapy. Dr. Dammai’s post-doctoral training at the Salk Institute for Biological Studies, La Jolla, California and University of California San Diego (UCSD) was followed by university faculty position as a NIH/National Cancer Institute (NCI)-funded (RO1 grant) Principal Investigator (Group Leader) and College of Medicine Assistant Professor at the NCI-designated Hollings Cancer Center, Charleston for 11 years prior to stepping outside academics to lead translational research in private biotech industry and subsequently partnership in entrepreneurial ventures. Dr.Dammai's PhD work focused on successful design and pre-clinical testing of catalytic RNAs (ribozymes) as RNA therapeutics approach to reverse Rheumatoid Arthritis (RA) disease progression. Dr.Dammai's subsequent research studies firmly stand as landmark discoveries of fundamental mechanisms in biology. Dr.Dammai served as an External Director of Research for private biotech companies involved in biologics discovery and pre-clinical/clinical development. While in academia, Dr.Dammai's research programs were funded by National Institutes of Health (NIH/NCI) and US Department of Defense (DOD) and his university leadership included faculty senator, Institutional Advancement Committee member, advisory committee member for Cancer Proteomics, advisory committee member for Biological Imaging Core Facility, and Director and c0-Director of PhD and MD/PhD programs in Molecular and Cell Biology. He served as an area expert in translational medicine for a number of years for American Cancer Society (ACS), DOD, National Aeronautics and Space Administration (NASA) and the Italian Ministry of Health, Italy. Dr.Dammai has the breadth of knowledge in diverse fields of biomedical sciences and bioengineering, especially in Cell & Gene Therapy (ATMP) areas with respect to R&D, CMC and MS&T. He is an expert in RNA-, Gene - and Cell therapeutics R&D, manufacturing and pre/clinical development. Dr.Dammai led the development of novel tumor seeking vehicles to target kidney cancers by modifying Sindbis Virus genome for tumor-specific delivery of ‘smart’ therapeutic payloads and oncolytic self-amplifying RNA (samRNA). Dr.Dammai’s research identified tumor-specific “neoantigens” and unique surface/secreted proteins for kidney cancers that formed the basis for designing these novel strategies to activate immune recognition of solid tumors. Dr.Dammai is published in top-tier journals such as CELL, Nature Cell Biology, Genes & Development, Molecular & Cellular Biology, Cancer Research, Journal of Biological Chemistry, Gene Therapy etc. Dr.Dammai also served as President/CEO of Biosimilars & Biologics Inc., a venture promoted by DMSC, which recently exited. Pubmed Publications
Operations Update
Dammai-Morgan Scientific Consultants LLC partners have recently voted to wind down and end operations. As of 2023, DMSC LLC completed its existing contractual obligations and proceeded to dissolve the company.
